THERAPY FOR TREATING CANCER BY INTRATUMORAL AND/OR INTRAVENOUS ADMINISTRATION OF RECOMBINANT MVA CODING 4-1BBL (CD137L) AND/OR CD40L Russian patent published in 2024 - IPC A61K39/285 A61K35/76 C12N7/01 A61P35/00 

FIELD: medicine.

SUBSTANCE: group of inventions relates to cancer therapy. Disclosed is a method for inducing an enhanced inflammatory response in a cancer of a subject, involving the intratumoral administration to a subject of a recombinant modified vaccinia virus (MVA), containing a first nucleic acid coding a first heterologous tumor-associated antigen (TAA), a second nucleic acid coding 4-1BBL antigen, and a third nucleic acid encoding the CD40L antigen. Also disclosed is a pharmaceutical composition for inducing an enhanced inflammatory response in a cancer of a subject and/or reducing the size of the tumor, containing a pharmaceutically acceptable carrier and said recombinant MVA.

EFFECT: introduction of recombinant MVA generates an enhanced inflammatory response in a tumor compared to an inflammatory response, generated by an intratumoral injection of a recombinant MVA virus containing a first and a second nucleic acid coding a heterologous TAA and 4-1BBL antigen, or compared to the inflammatory response generated by the introduction of recombinant MVA, 4-1BBL antigen and CD40L antigen per se.

13 cl, 29 dwg, 39 ex